EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Viva Biotech Holdings's Enterprise Value is $492.2 Mil.
Viva Biotech Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $0.4 Mil. Therefore, Viva Biotech Holdings's EV-to-FCF for today is 1,149.91.
The historical rank and industry rank for Viva Biotech Holdings's EV-to-FCF or its related term are showing as below:
VBIZF'
s EV-to-FCF Range Over the Past 10 Years
Min: -828.4 Med: -12.41 Max: 1181.34
Current: 1181.34
During the past 8 years, the highest EV-to-FCF of Viva Biotech Holdings was 1181.34. The lowest was -828.40. And the median was -12.41.
VBIZF's EV-to-FCF is ranked worse than 98.56% of 418
companies
in the Biotechnology industry
Industry Median: 3.73
vs VBIZF: 1181.34
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Viva Biotech Holdings's EV-to-FCF
For the Biotechnology subindustry, Viva Biotech Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viva Biotech Holdings's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Viva Biotech Holdings's EV-to-FCF falls into.
Viva Biotech Holdings's current Enterprise Value is $492.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Viva Biotech Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $0.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Viva Biotech Holdings's PE Ratio (TTM) for today is calculated as:
Viva Biotech Holdings's share price for today is $0.2213.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Viva Biotech Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.013.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Viva Biotech Holdings EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Viva Biotech Holdings's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Viva Biotech Holdings is an integrated drug discovery platform. The company's operating segment includes Drug discovery services and Contract Development Manufacture Organisation (CDMO) and commercialisation services. It generates maximum revenue from the Contract Development Manufacture Organisation (CDMO) and commercialisation services segment. The Contract Development Manufacture Organisation (CDMO) and commercialisation services segment include contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates, and formulations. Geographically, the company generates a majority of its revenue from the United States of America, and the rest from the European Union, Chinese Mainland, Africa, and other regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VBIZF has been successfully added to your 